Ninety-one patients were allocated randomly to three groups to receive 1% ropivacaine 10 ml, 0.5% ropivacaine 20 ml or 0.5% bupivacaine 20 ml extradurally. Intermittent sensory (pinprick) and motor (Bromage scale) assessments of the block produced were recorded, with an assessment of the quality of the block and the requirement for supplementary analgesia. There was little difference between the groups in frequency, onset, duration or spread of sensory block. However, the motor block produced by 0.5% ropivacaine was less intense and of shorter duration than that with bupivacaine. The block produced by the smaller volume of ropivacaine was less reliable clinically than the larger, more dilute, solution and more anaesthetic supplements were required in that group. Cardiovascular changes were similar in all three groups. The peak plasma concentration of ropivacaine was significantly greater and T1/2 significantly shorter than those of bupivacaine, although no patient showed any features of systemic toxicity. The systemic kinetics of ropivacaine were not influenced significantly by varying the concentration or volume administered.
The clinical and pharmacokinetic properties of ropivacaine and bupivacaine, both 5 mg/mL, used in axillary plexus block were compared in 60 patients in this randomized, double-blind, parallel-group study. The axillary plexus was identified with a nerve stimulator and 30, 35, or 40 mL of drug, depending on body weight, was injected into the perivascular sheath. In 20 patients, venous blood samples for the pharmacokinetic measurement were obtained over 24 h. The median onset times for anesthesia and complete motor block were in the range of 12-48 min and 5-20 min, respectively. Thirty-eight percent of patients in the ropivacaine group and 29% in the bupivacaine group needed additional nerve block(s) or supplementary analgesia and 7% in the bupivacaine group needed general anesthesia for surgery. Anesthesia was achieved in 52%-86% of the evaluated six nerves in the ropivacaine group and in 36%-87% in the bupivacaine group; the lowest figures were seen in the musculocutaneous nerve. In the pharmacokinetic study the mean peak plasma concentrations (Cmax) were 1.28 +/- 0.21 mg/L in the ropivacaine group and 1.28 +/- 0.47 mg/L in the bupivacaine group and the median times to peak plasma concentration (tmax) were 0.86 h and 0.96 h, respectively. The median terminal half-lives (t1/2) were 7.1 h and 11.5 h in the ropivacaine group and the bupivacaine group, respectively (P = 0.07). No statistically significant differences were found between ropivacaine and bupivacaine in either the clinical or the pharmacokinetic comparisons.
In an open study we have investigated the efficacy of 20 ml of 0.75% ropivacaine (7.5 mg ml-1) to provide extradural anaesthesia for elective Caesarean section. Plasma concentrations (total and free) were estimated in the mother and neonate. Anaesthesia was effective and safe. Plasma concentrations of ropivacaine in the mother and neonate were within safe limits and consistent with previous studies. Two mothers received accidental i.v. injections of ropivacaine 75 mg and 150 mg, respectively, without serious adverse effects.
Forty women having requested extradural analgesia for labour were allocated randomly to receive 0.5% ropivacaine or bupivacaine 10 ml as the main dose. When a top-up was requested, 0.25% ropivacaine or bupivacaine 10 ml was given (the same drug as the main dose). The study ended when a second top-up was requested or delivery of the baby occurred. Pain from two contractions was assessed before extradural block by visual analogue scoring and thereafter with every contraction. Sensory block and motor block were assessed at intervals. The only significant difference between the groups was a shorter onset of pain relief after the main dose of bupivacaine; there were no other significant differences in duration, onset of pain relief after top-up, quality of analgesia, spread of sensory block and motor block between the groups. Cardiovascular changes and neonatal outcome were similar in the two groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.